Fennec Pharmaceuticals is a small stage biotechnology company focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients.
Fennec Provides Business Update And Reports Third Quarter 2017 Results Mon, 13 Nov 2017 11:00:00 +0000 During the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study Study met primary endpoint indicating a significant reduction in cisplatin induced hearing loss without ...
Fennec banks positive results on heels of move to Nasdaq Thu, 19 Oct 2017 13:00:11 +0000 On the heels of making its Nasdaq debut – moving from an over-the-counter market it started trading on several years ago – Research Triangle Park-based Fennec Pharmaceuticals (FENC) has banked positive Phase 3 results for its product for the prevention of hearing loss in pediatric cancer patients receiving chemotherapy. The Phase 3 results – for Fennec’s sodium thiosulfate therapy called PEDMARK – were presented at the International Society of Pediatric Oncology (SIOP) 2017 meeting over the weekend in Washington, D.C. They showed “significant improvement in the prevention of hearing loss” in children receiving PEDMARK with chemotherapy over those receiving chemotherapy alone, says Fennec Chief Financial Officer Robert Andrade. “A little bit of hearing loss is a big deal,” says Andrade, noting the impact Fennec envisions PEDMARK continuing to make for pediatric cancer patients.
IIROC Trade Halt - Fennec Pharmaceuticals Inc. Wed, 13 Sep 2017 13:38:00 +0000 Toronto, Ontario--(Newsfile Corp. - September 13, 2017) - The following issues have been halted by IIROC: Company: Fennec Pharmaceuticals Inc. TSX Symbol: FRX (all issues) ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.